Multiple Insiders Sold Protagonist Therapeutics Shares Presenting Weak Signs For Investors

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. Knowing whether insiders are buying is usually mo

Simply Wall StMay 4 22:21

We Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Soon

Yahoo FinanceApr 29 20:22

Polycythemia Pipeline Insight 2024, Featuring Protagonist Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, Imago BioSciences, Incyte, Italfarmaco, Lynk and Promedior

Yahoo FinanceApr 18 15:53

Turnstone Biologics Appoints William Waddill to Its Board of Directors

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure

GlobeNewswireApr 16 21:00

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

You may think that with a price-to-sales (or "P/S") ratio of 26.3x Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a stock to avoid completely, seeing as almost half of all the Biotechs companies in t

Simply Wall StApr 13 22:01

Hemochromatosis Pipeline Insight Report 2024, Featuring Protagonist Therapeutics, Sirnaomics and Bond Biosciences

Yahoo FinanceApr 11 21:31